$BCDA

Altman Peter purchased $5K of BCDA

Altman Peter (President and CEO) purchased 5,400 shares of BioCardia, Inc. (BCDA) at $0.96 on 2026-07-08.

Original reporting
SEC EDGAR · Altman Peter
Published Jul 8, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BCDA
Bullish
low confidence
Mentioned
$BCDA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDABullishLow
01

Why it matters

A CEO open-market purchase is a positive sentiment datapoint, but the text lacks any fundamental update (earnings, trial results, financing, or regulatory action).

02

Market read

Traders may note the insider buy as a small bullish sentiment input, but it is unlikely to drive a major repricing without additional catalysts.

03

What to watch

The filing notes no 10b5-1 plan and provides no rationale; without follow-on disclosures (guidance, trial updates, financing), the signal may be weak.

Relevance 4/10Novelty 5/10Timing: filed on 2026-07-08 (same day as reported purchase)

Background

The article is a SEC Form 4 insider transaction disclosure for BioCardia, Inc.

Company-level read

Ticker impact

$BCDABullishLow confidence
Context

BioCardia CEO Altman Peter filed a Form 4 for an open-market purchase of 5,400 shares at $0.9645 on 2026-07-08.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 insider buys can be read as confidence signals, but the article provides no accompanying operational or financial catalyst, and the transaction value is modest.

Market effects

No sector-wide implications; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be routine liquidity or compensation-related and may not reflect a new view on near-term prospects.

Key entities

  • BioCardia, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Altman Peter

    President and CEO who purchased 5,400 shares on 2026-07-08.

Related articles